arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Edesa Biotech, Inc.

EDSA
$5.56 ▲ +0.46 (+9.02%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
50 Visible periods
26 Metrics
Peer-ranked Benchmarks
Price Chart
30
Health
Poor
Bearish
auto_awesome

Analytical Summary

Edesa Biotech, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $47.5M
Dividend Yield
Revenue Growth None
Op. Margin None
ROIC -42.1%
FCF / Share $-0.24
Trailing P/E
Price / Book 4.9x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

50-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
Net Income Profit after all expenses
$-4.22M
↓ -165.2%
FCF / Share Free cash flow per share
$-0.24
↑ +9.8%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
15
Cash Quality
66

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 14 years · 50 quarters